

NEW VENTURETEC

subject: **Press Release**
Date: November 6, 2006

For further information:
Peter Friedli
Freigutstrasse 5
8002 Zürich
Tel: 044/283 29 00
Email: peter.friedli@friedlicorp.ch

New Venturetec with good results for the fiscal year 2005 / 2006 per September 30, 2006

Zürich, November 6, 2006. New Venturetec closed the fiscal year 05/06, ended September 30, 2006, with a profit of USD 10'088'153, against USD 22'889'427 in the fiscal year 04/05. The net asset value per share increased from USD 21.95 to USD 23.97 which equals 9.2% during the reporting period; in CHF respectively from 27.88 to 29.96 or 7.5%. The share price in the same period increased from CHF 24.00 to CHF 26.20, or 9.2%.

The net gain on investments of the reporting period is USD 17'730'768 compared to USD 38'365'322 in the same period 2005. The main reason for the increase is Basilea Pharmaceutica's traded stock by 42.4%.

The operational progress of the portfolio companies is evident. As of September 30, 2006, New Venturetec had ten investments with four investments valued higher than the investment costs, four at cost and two below investment costs. The net asset value is USD 119'835'283 compared to USD 94'823'590 paid-in and additional paid-in capital. This represents a total return on paid-in and additional paid-in capital of 26.4% as per September 31, 2006. There was no management fee paid in the reporting period but rather accrued. The board remuneration for the reporting period was CHF 15'000.

The annual report, including financial statements for the reporting period can be downloaded from www.newventuretec.com.

New Venturetec is a publicly traded Swiss investment company (SWX: NEV) which invests directly in Venture Capital Companies in the USA.

The Ordinary Shareholder Meeting takes place November 28, 2006 at the UBS Conference Center Grüenhof, Nüscherstrasse 9, 8001 Zurich from 11.45 until 13.30. The following companies will present: Prolexys Pharmaceuticals, Basilea Pharmaceutica and Osiris Therapeutics.